Oncodevelopmental markers : biologic, diagnostic, and monitoring aspects / edited by William H. Fishman.

Date:
1983
Catalogue details

Licence: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)

Credit: Oncodevelopmental markers : biologic, diagnostic, and monitoring aspects / edited by William H. Fishman. Source: Wellcome Collection.

    18/464 (page XIV)
    xiv Contributors M. J. Escribano (315), Laboratoire d'Immunochimie, Institut de Recherches Scientifiques sur le Cancer, 94802 Villejuif, France William H. Fishman (3), Cancer Research Center, La Jolla Cancer Research Foundation, La Jolla, California 92037 Robert F. Gagel (221), Departments of Medicine and Cell Biology, Baylor College of Medicine, Houston, Texas 77211 and Veterans Administration Medical Center, Houston, Texas 77211 Ronald B. Herberman (409), Biological Therapeutics Branch, Biological Re¬ sponse Modifiers Program, Division of Cancer Treatment, National Cancer Institute, Frederick, Maryland 20205 David Kelsey (37), Department of Pharmacology, Baylor College of Medicine, Houston, Texas 77030 Young S. Kim (299), Gastrointestinal Research Laboratory, Veterans Admin¬ istration Medical Center, San Francisco, California 94121, and Department of Medicine, University of California, San Francisco, San Francisco, Cal¬ ifornia 94121 Hilary Koprowski (155), The Wistar Institute of Anatomy and Biology, Phila¬ delphia, Pennsylvania 19104 Paul H. Lange (241), Department of Urologie Surgery, University of Minnesota College of Health Sciences, Minneapolis, Minnesota, and Veterans Admin¬ istration Medical Center, Minneapolis, Minnesota 55417 D. J. R. Laurence (131), Ludwig Institute for Cancer Research (London Branch), Royal Marsden Hospital, Sutton, Surrey SM2 5PX, England Lawrence J. Mclntyre (299), Gastrointestinal Research Laboratory, Veterans Administration Medical Center, San Francisco, California 94121, and De¬ partment of Medicine, University of California, San Francisco, San Fran¬ cisco, California 94121 Mani Menon (279), Division of Urology, Washington University School of Medicine, St. Louis, Missouri 63110 A. M. Neville (131), Ludwig Institute for Cancer Research (London Branch), Royal Marsden Hospital, Sutton, Surrey SM2 5PX, England Derek Raghavan (109), Department of Medical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia, and Ludwig Institute for Cancer Research, Camperdown, New South Wales, Australia Raymond W. Ruddon (87), Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan 48109 Erkki Ruoslahti (21), Cancer Research Center, La Jolla Cancer Research Foun¬ dation, La Jolla, California 92037 Markku Seppälä (373), Department 1 of Obstetrics and Gynecology, Univer¬ sity Central Hospital, Helsinki, Finland Marjatta Son (37), Department of Pharmacology, Baylor College of Medicine, Houston, Texas 77030